Frontierby eninvs

Language: EN · RU

← Region

Aurobindo Pharma (AUROPHARMA) USD

At a glance: strengths & risks
✓Revenue growing (+17% y/y, Q1 2026)✓Profit growing (+25% y/y, Q1 2026)✓Low leverage (0.1x EBITDA)✓Cheaper than own history (EV/EBITDA 19.5 vs avg 36.1)

Sector: Pharmaceuticals

IN_AUROPHARMA

Price chart

1 648.2 INRDay -2.09%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
1 648.2 INR · -2.09%
Market cap
10.0 bn USD

Growth

Δ revenue y/y
8.6%
Δ EBITDA y/y
9.0%

Multiples

P/E (LTM)
26.0x
3y avg: 19.6x
P/B (FY)
2.5x
P/E (ann.)
22.4x
EV/EBITDA (LTM)
19.5x
3y avg: 36.1x
EV/EBITDA (ann.)
18.3x

Cash return

Dividend yield
—
FCF yield (LTM)
—

Value creation

fundamental value/yr, % of market cap
Value created / year
+9.7%
↓ details

Liquidity

Daily turnover (listing)
1.3 bln INR

Shares: connector/market_inputs

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB USDOperating profitB USDD&AB USDEBITDAB USDNet profitB USDOperating CFB USDCapex + M&AB USDAssetsB USDEquityB USDROE (annualized)Net debtB USDSource
2026-06-30Q2 2026 (3M)PARTIAL1.0
y/y 8.6%
0.2
y/y 8.1%
0.1
y/y 11.5%
0.2
y/y 9.0%
0.1
y/y 16.3%
———
y/y —
4.0
y/y 5.2%
11.1%≈ 4.8—
2026-03-31FY 2026 (12M)OK—
y/y 0.4%
—
y/y -2.9%
—
y/y 4.4%
—
y/y -1.2%
—
y/y -5.1%
——6.2
y/y 7.0%
4.0
y/y 5.7%
9.7%4.8—
2025-12-31Q4 2025 (3M)PARTIAL1.0
y/y 3.2%
0.1
y/y 3.5%
0.1
y/y —
0.2
y/y 40.3%
0.1
y/y 3.0%
———
y/y —
3.9
y/y 8.0%
3.5%≈ -78.5—
2025-09-30Q3 2025 (3M)OK1.0
y/y 2.6%
0.1
y/y 1.8%
0.0
y/y —
0.2
y/y 30.2%
0.1
y/y 0.2%
——5.9
y/y 3.1%
3.9
y/y 7.0%
10.1%-78.5Link
2025-06-30Q2 2025 (3M)PARTIAL0.9
y/y -0.5%
0.1
y/y -4.8%
0.0
y/y —
0.2
y/y 27.5%
0.1
y/y -13.3%
———
y/y —
3.8
y/y 6.3%
10.0%≈ 23.7—
2025-03-31FY 2025 (12M)OK—
y/y 5.3%
—
y/y 9.5%
—
y/y 0.8%
—
y/y 7.3%
—
y/y 5.9%
——5.8
y/y 7.8%
3.8
y/y 6.8%
10.9%23.7—
2024-12-31Q4 2024 (3M)PARTIAL0.9
y/y 6.9%
0.1
y/y 1.1%
—
y/y —
0.1
y/y 1.1%
0.1
y/y -11.1%
———
y/y —
3.6
y/y 6.4%
3.7%≈ -48.9Link
2024-09-30Q3 2024 (3M)OK0.9
y/y 6.5%
0.1
y/y 18.5%
—
y/y —
0.1
y/y 18.5%
0.1
y/y 6.5%
——5.7
y/y 8.6%
3.7
y/y 8.6%
10.8%-48.9Link
2024-06-30Q2 2024 (3M)PARTIAL0.9
y/y —
0.1
y/y —
—
y/y —
0.1
y/y —
0.1
y/y —
———
y/y —
3.6
y/y —
12.3%≈ 29.1Link
2024-03-31FY 2024 (12M)OK—
y/y 15.6%
—
y/y 73.6%
—
y/y 21.3%
—
y/y 56.4%
—
y/y 63.3%
——5.4
y/y 11.4%
3.6
y/y 9.6%
11.0%29.2—
2023-12-31Q4 2023 (3M)PARTIAL0.9
y/y —
0.1
y/y —
—
y/y —
0.1
y/y —
0.1
y/y —
———
y/y —
3.4
y/y —
4.4%≈ -53.6Link
2023-09-30Q3 2023 (3M)OK0.9
y/y —
0.1
y/y —
—
y/y —
0.1
y/y —
0.1
y/y —
——5.3
y/y —
3.4
y/y —
11.0%-53.6Link
2023-03-31FY 2023 (12M)OK3.0
y/y —
0.3
y/y —
0.2
y/y —
0.5
y/y —
0.2
y/y —
0.3-27.24.9
y/y —
3.3
y/y —
—4.7—

Revenue & EBITDA

RevenueEBITDA

Quarterly values (INR mln)

02004006008001 0002024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Year-over-year change

-20%0%20%40%2024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q2

Cash flow

Net debt / cash (INR mln)

-100 000-75 000-50 000-25 000025 0002024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 q12026 q22026 q4

Profit and cash

Profit is cash-backed
In a typical year of 2022–2026 operating cash flow came to 1.24x of reported net profit; after capex, 0.40x.
year20222023202420252026
cash flow / profit1.89x1.24x0.77x1.13x1.58x
accruals, % of assets—-1.1%1.6%-0.9%-3.5%
net debt / EBITDA 0.1x · capex 1.9x of depreciation
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: +9.7%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30)
= (203 − 186) × 3.84
64
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (9 988 + 4 848) ÷ 778
19.1x
3. Target multiple
(Current EV/EBITDA + 11) ÷ 2
= (19.1 + 11) ÷ 2
15.0x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= 18 879 + 0 + 0 − 0
0
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (64 × 15.0 + 0) ÷ 9 988
+9.7%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • FCF (LTM) approximated by latest FY (ended 2026-03-31, before the latest reported period 2026-06-30)
  • dividends/buybacks not in data - balance cash flow uses net-debt change only
  • net-cash rise stripped: net debt fell while EBITDA declined and no share dilution measured (likely equity raise / recapitalisation)

Revenue growth & acceleration

Growth steady →
Last-year revenue growth +6% vs +9% the year before — a -2.9 pp move. 3-year CAGR +11%.
revenue growth by year: 2024 +17% · 2025 +9% · 2026 +6%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2025-08-084 INREx-dividend: 4 INR per sharePaidYahoo Finance (ex-div)
2024-02-201.5 INREx-dividend: 1.5 INR per sharePaidYahoo Finance (ex-div)
2023-11-203 INREx-dividend: 3 INR per sharePaidYahoo Finance (ex-div)
2023-02-173 INREx-dividend: 3 INR per sharePaidYahoo Finance (ex-div)
2022-06-064.5 INREx-dividend: 4.5 INR per sharePaidYahoo Finance (ex-div)
2022-02-181.5 INREx-dividend: 1.5 INR per sharePaidYahoo Finance (ex-div)
2021-11-171.5 INREx-dividend: 1.5 INR per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Aurobindo Pharma (AUROPHARMA) — from primary filings.

Frequently asked questions

What is Aurobindo Pharma (AUROPHARMA)'s P/E ratio?
Aurobindo Pharma (AUROPHARMA) trades at a P/E of 26.0x (price to trailing 12-month earnings).
What is Aurobindo Pharma (AUROPHARMA)'s EV/EBITDA?
Aurobindo Pharma (AUROPHARMA) trades at 19.5x EV/EBITDA.
What is Aurobindo Pharma (AUROPHARMA)'s P/B ratio?
Aurobindo Pharma (AUROPHARMA) trades at a P/B of 2.5x.
What is Aurobindo Pharma (AUROPHARMA)'s return on equity (ROE)?
Aurobindo Pharma (AUROPHARMA)'s ROE is 11.1%.
What is Aurobindo Pharma (AUROPHARMA)'s market capitalization?
Aurobindo Pharma (AUROPHARMA)'s market cap is 10.0 bn USD.

See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map